European Commission approves Amneal's Adcomfo omalizumab biosimilar to Xolair

Amneal has received European Commission approval for Adcomfo, an omalizumab biosimilar to Xolair, covering several allergic and inflammatory conditions and expanding competition in the European biologics market.
Amneal announced on 17 November 2026 that the European Commission had approved Adcomfo (omalizumab), a biosimilar to Xolair, for specified indications including severe allergic asthma, chronic spontaneous urticaria and chronic rhinosinusitis with nasal polyps.
The biosimilar was developed by Kashiv BioSciences in collaboration with Alvotech, with European commercialisation rights held by ADVANZ PHARMA; the decision follows UK authorisation in March 2026, while the separate US application remains under FDA review, making this a new European approval rather than a US regulatory milestone.
Field | Content |
Company | Amneal |
Medicine | Adcomfo (omalizumab) |
Reference Medicine | Xolair |
Regulatory Authority | European Commission |
Approval Date | 17 November 2026 |
Approval Type | EU biosimilar marketing authorisation |
Therapeutic Areas | Allergy immunology and respiratory medicine |
Indication One | Severe allergic asthma |
Indication Two | Chronic spontaneous urticaria |
Indication Three | Chronic rhinosinusitis with nasal polyps |
Product Classification | Monoclonal antibody biosimilar |
Development Company | Kashiv BioSciences |
Development Collaboration | Alvotech |
European Commercialisation Rights | ADVANZ PHARMA |
Earlier UK Approval | March 2026 |
US Regulatory Status | FDA application under review according to supplied summary |
Primary Source | https://investors.amneal.com/news/press-releases/press-release-details/2026/Amneal-Announces-European-Approval-of-Adcomfo-Omalizumab-a-Biosimilar-to-XOLAIR/default.aspx |
Discover how nuaxia can support your next medical education initiative:
Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector
Contact us on: support@nuaxia.com


Comentários